PRMT5 and breast carcinoma: In glioblastoma and breast cancer models, PRMT5 inhibitors (e.g., EPZ015666, pemrametostat) have been shown to overcome resistance to mTOR inhibitors (e.g., PP242) and CDK4/6 inhibitors (e.g., abemaciclib, palbociclib, ribociclib) [113, 595].